Financial Data and Key Metrics Changes - The company reported a significant year-over-year total revenue growth of 22%, with full-year 2025 revenues of $407.3 million, compared to $333.6 million in 2024 [32] - XPHOZAH revenues grew to $274.2 million, an increase of 73% compared to the full year of 2024 [33] - The net loss for 2025 was $61.6 million, or $0.26 per share, compared to a net loss of $39.1 million, or $0.17 per share, for 2024 [36] Business Line Data and Key Metrics Changes - IBSRELA achieved a remarkable revenue growth of 73% compared to 2024, with a 61% year-over-year growth in the fourth quarter [7][11] - XPHOZAH experienced a 9% increase in total dispenses and a 41% increase in paid dispenses when excluding Medicare compared to 2024 [18] - The IBS-C market grew by 11% in 2025, with nearly 7 million prescriptions written [13] Market Data and Key Metrics Changes - The IBS-C market continues to grow in double digits, indicating a robust demand for treatment options [12] - The company noted that 77% of patients on a secretagogue report continuing symptoms, highlighting a significant unmet need in the market [13] Company Strategy and Development Direction - The company aims to significantly grow IBSRELA and maintain momentum for XPHOZAH, with a focus on expanding its pipeline to address unmet medical needs [5][10] - A new patent for the commercial formulations of IBSRELA and XPHOZAH, expiring in 2042, was issued, which is part of the strategy to build a comprehensive intellectual property portfolio [8] - The company plans to invest in three key areas: optimizing prescriber engagement, improving prescription pull-through, and increasing patient activation [14][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching the revenue guidance for IBSRELA of $410 million to $430 million in 2026, representing at least 50% year-over-year growth [37] - The company anticipates that IBSRELA will reach $1 billion in revenue by 2029, driven by continued adoption among IBS-C patients and potential growth from patients with CIC [39] - Management emphasized a disciplined approach to capital allocation and investments to drive growth and achieve profitability [31][42] Other Important Information - The company finished 2025 with a strong cash position of $264.7 million, an increase from $250.1 million at the end of 2024 [37] - The company has generated positive cash flow for two consecutive quarters due to growing revenue [37] Q&A Session Summary Question: Confidence in IBSRELA volume growth to reach $430 million guidance - Management expressed strong confidence in the guidance, citing the large patient population needing alternatives to current treatments [47] Question: Cadence of R&D and SG&A step-ups for 2026 - Management indicated a 25% increase in operating expenses, with a focus on growth in both commercial and R&D areas [56] Question: Expectations for the CIC trial and dose levels - Management clarified that the trial includes multiple doses to evaluate efficacy and safety, with a focus on finding the optimal dose [66] Question: Distinctions in the CIC market compared to other treatments - Management highlighted the need for different mechanisms of action in treating CIC, similar to IBS-C, due to the fluidity between the two conditions [73] Question: Long-term growth for XPHOZAH post-2026 - Management noted that they do not benefit from Medicare base rate adjustments and are focused on ensuring patient access regardless of coverage [88]